drug · protein
atacicept
pre_registrationupdated 3mo agoby $VERA Vera Therapeutics, Inc.🔗 ChEMBL
community read0 votes
Protein drug with a maximum clinical stage of Phase 3 (across all indications), with 8 investigational indications.
targets
Tumor necrosis factor ligand superfamily member 13BTumor necrosis factor ligand superfamily member 13
all catalysts(0)
nothing on the calendar yet
Trials studying atacicept
News(5)
- Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugsBoulevard Bio has strolled out of stealth with $65 million in funding from Deerfield Management and three autoimmune disease candidates.fiercebiotech · 3d ago
- Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvalsThe FDA is currently reviewing Vertex Pharmaceuticals’ povetacicept, with a target action date of Nov. 30. If approved, the drug could benefit from campaigns from Novartis and Vera Therapeutics for…biospace · 25d ago
- Vera's IgAN approval kicks off competition with OtsukaVera Therapeutics’ fusion protein atacicept got an accelerated approval on Tuesday for a chronic autoimmune disease that damages the kidneys. The drug will be marketed as Trutakna for immunoglobuli…endpoints · 1mo ago
- Vera Therapeutics wins FDA nod for closely watched kidney disease drugThe clearance marks another step forward in treatment for IgA nephropathy and sets up a commercial battle with Otsuka, which brought a similar medication to market last year.biopharma_dive · 1mo ago
- STAT+: Radiopharmaceutical shows promise in post-Pluvicto settingAbivax's ulcerative colitis data, Fulcrum's scrapped sickle cell drug, and more biotech news from The Readoutstat · 2mo ago
Data sources
last refreshed 37m ago
Found something off?
comments(0)
5-min edit window · permanent after that